248 related articles for article (PubMed ID: 16507915)
1. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution.
Touat Z; Ollivier V; Dai J; Huisse MG; Bezeaud A; Sebbag U; Palombi T; Rossignol P; Meilhac O; Guillin MC; Michel JB
Am J Pathol; 2006 Mar; 168(3):1022-30. PubMed ID: 16507915
[TBL] [Abstract][Full Text] [Related]
2. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model.
Dai J; Louedec L; Philippe M; Michel JB; Houard X
J Vasc Surg; 2009 Mar; 49(3):719-27. PubMed ID: 19028049
[TBL] [Abstract][Full Text] [Related]
3. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury.
Bright JM; Dowers K; Powers BE
Vet Ther; 2003; 4(1):35-46. PubMed ID: 12756634
[TBL] [Abstract][Full Text] [Related]
4. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
5. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
6. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
Berny-Lang MA; Jakubowski JA; Sugidachi A; Barnard MR; Michelson AD; Frelinger AL
J Am Heart Assoc; 2013 May; 2(3):e000026. PubMed ID: 23676293
[TBL] [Abstract][Full Text] [Related]
7. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
8. Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty.
Fredrickson BJ; Turner NA; Kleiman NS; Graziadei N; Maresh K; Mascelli MA; Effron MB; McIntire LV
Circulation; 2000 Mar; 101(10):1122-9. PubMed ID: 10715258
[TBL] [Abstract][Full Text] [Related]
9. Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.
Graff J; Andries D; Elsner M; Westrup D; Bassus S; Franz N; Klinkhardt U; Harder S
Br J Clin Pharmacol; 2001 Jun; 51(6):577-82. PubMed ID: 11422017
[TBL] [Abstract][Full Text] [Related]
10. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists.
Morel O; Hugel B; Jesel L; Mallat Z; Lanza F; Douchet MP; Zupan M; Chauvin M; Cazenave JP; Tedgui A; Freyssinet JM; Toti F
J Thromb Haemost; 2004 Jul; 2(7):1118-26. PubMed ID: 15219195
[TBL] [Abstract][Full Text] [Related]
11. Expression of markers of platelet activation and the interpatient variation in response to abciximab.
Bihour C; Durrieu-Jaïs C; Macchi L; Poujol C; Coste P; Besse P; Nurden P; Nurden AT
Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):212-9. PubMed ID: 9974400
[TBL] [Abstract][Full Text] [Related]
12. [Variable response to the biological inhibition of platelets by abciximab in patients subjected to percutaneous coronary angioplasty].
Galeote G; López Pastor A; Cárcamo C; Sobrino N; Calvo L; García Muñoz S; Hussein M; Férnandez-Chacón JL; Sobrino JA
Rev Esp Cardiol; 2001 Nov; 54(11):1256-63. PubMed ID: 11707234
[TBL] [Abstract][Full Text] [Related]
13. Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.
Speich HE; Furman RR; Lands LT; Moodie GD; Jennings LK
J Thromb Thrombolysis; 2013 Jul; 36(1):31-41. PubMed ID: 23073747
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
[TBL] [Abstract][Full Text] [Related]
15. Combined thrombolysis with abciximab favourably influences platelet-leukocyte interactions and platelet activation in acute myocardial infarction.
Szabo S; Etzel D; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM
J Thromb Thrombolysis; 2005 Dec; 20(3):155-61. PubMed ID: 16261288
[TBL] [Abstract][Full Text] [Related]
16. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Furman MI; Krueger LA; Linden MD; Fox ML; Ball SP; Barnard MR; Frelinger AL; Michelson AD
J Thromb Haemost; 2005 Feb; 3(2):312-20. PubMed ID: 15670038
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
18. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
Wu KK; Willerson JT
Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
[No Abstract] [Full Text] [Related]
19. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa inhibitors: basic and clinical aspects.
Nurden AT; Poujol C; Durrieu-Jais C; Nurden P
Arterioscler Thromb Vasc Biol; 1999 Dec; 19(12):2835-40. PubMed ID: 10591658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
